Mixed response to EU’s compulsory licence position

Charlotte Kilpatrick

December 10, 2020

European pharma sources respond to the European Commission’s IP Action Plan, saying COVID has shown that IP does not block access to medicine

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Topics

Charlotte Kilpatrick

Reporter Managing IP

Charlotte reports on patent-related issues. She often covers the European market, focusing on developments including FRAND, licensing and trade secrets. She is particularly interested in how new technologies affect IP challenges in the pharmaceutical industry.

More from across our site

The UPC story so far: German dominance and CMS ‘liability’ risk

European lawyers tell Managing IP how the legal market is reacting to the first few months of the UPC and why cases are set to take off

Rory O’Neill, September 21, 2023

Federal Circuit affirms one-year case ban for Newman

The ban could be extended or cancelled, depending on whether Judge Pauline Newman cooperates with an investigation, the Judicial Council of the Federal Circuit stated

Rani Mehta, September 20, 2023

Hard sell: lawyers struggle to move firms during China downturn

Sources say some China-based lawyers are prepared to take large pay cuts to join stable practices, but most firms are sceptical about new hires

Sukanya Sarkar, September 20, 2023

Weekly take: IP judge’s ChatGPT use was jolly good … for now

Lord Justice Colin Birss used ChatGPT to help him write a judgment, a development that has generated plenty of debate but which is perhaps inevitable

Max Walters, September 19, 2023

Breaking: UPC hits NanoString with European sales ban

The decision marks the first time the Unified Patent Court has issued a preliminary injunction after an oral hearing involving both sides in a dispute

Rory O’Neill, September 19, 2023